Cost-effectiveness of FDA variance for blood collection from individuals with hereditary hemochromatosis at a 398-bed hospital-based donor center

Gribble, D.M.; Chaffin, D.J.; Bryant, B.J.

doi:10.21307/immunohematology-2019-251

.blurhash-client-img { display: none !important; }

Cost-effectiveness of FDA variance for blood collection from individuals with hereditary hemochromatosis at a 398-bed hospital-based donor center

Immunohematology

Volume 25 (2009): Issue 4 (December 2009)

By: D.M. Gribble, D.J. Chaffin and B.J. Bryant

Paid access

|Mar 2020

Authors

D.M. Gribble

Blood Services QA/QI Coordinator, North Colorado Medical Center, Colorado, United States

D.J. Chaffin

Blood Services, Summit Pathology, North Colorado Medical Center, Greeley, CO, United States

B.J. Bryant

Blood Bank Division, Blood Banking Technology Program, Pathology Residency Training Program, University of Texas Medical Branch, Galveston, TX, United States

DOI: https://doi.org/10.21307/immunohematology-2019-251 | Journal eISSN: 1930-3955 | Journal ISSN: 0894-203X

Journal RSS Feed

Language: English

Page range: 170 - 173

Published on: Mar 20, 2020

Published by: American National Red Cross

In partnership with: Paradigm Publishing Services

Publication frequency: 4 issues per year

Keywords:

hereditary hemochromatosis (HH),

Related subjects:

© 2020 D.M. Gribble, D.J. Chaffin, B.J. Bryant, published by American National Red Cross
This work is licensed under the Creative Commons License.

Previous article Volume 25 (2009): Issue 4 (December 2009)Next article